Oncology Drug Crash Course: Fam-Trastuzumab Deruxtecan-Nxki (Enhertu)

home / publications / rx-roadmap / oncology-drug-crash-course-fam-trastuzumab-deruxtecan-nxki-enhertu-

Alyssa Hall, FNP-BC, AOCNP;Donna Thomas, BSN, RN, OCN;Kellie Zeichner, BSN, RN, OCN

November 8th 2022

After demonstrating significant efficacy as a third-line treatment for patients with metastatic HER2-positive breast cancer, fam-trastuzumab deruxtecan-nxki has gained approval from the FDA for 5 indications and is under investigation across solid tumors.